SRR2932838
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.370
- G2M_CHECKPOINT+0.340
- ANGIOGENESIS+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
- SPERMATOGENESIS+0.260
- MITOTIC_SPINDLE+0.200
- UV_RESPONSE_DN+0.190
- MYC_TARGETS_V1+0.160
- WNT_BETA_CATENIN_SIGNALING+0.160
- PANCREAS_BETA_CELLS+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.510
- OXIDATIVE_PHOSPHORYLATION-0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- FATTY_ACID_METABOLISM-0.350
- PI3K_AKT_MTOR_SIGNALING-0.340
- P53_PATHWAY-0.330
- MTORC1_SIGNALING-0.320
- ALLOGRAFT_REJECTION-0.310
- COMPLEMENT-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0122214 | — | — | 0.933 |
| 2 | ERR2208889 | — | — | 0.915 |
| 3 | TCGA-AC-A2QH-01B-04R-A22O-07 | — | D | 0.913 |
| 4 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.897 |
| 5 | b0be4742-ccb7-48e2-b756-0c384321114e | — | — | 0.876 |
| 6 | SAMN03290896 | — | — | 0.863 |
| 7 | SRR10899974 | — | — | 0.862 |
| 8 | TCGA-XF-AAMG-01A-11R-A42T-07 | — | — | 0.859 |
| 9 | 0918cbd5-edd0-41c8-8b67-677f35ad4611 | — | — | 0.858 |
| 10 | 7478db87-0751-4771-941f-9fccdf01853d | — | — | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |